Highlights:

  • Signed a 2-year exclusive agreement to manufacture and distribute Khiron-branded medical cannabis products in Lima, Peru´s largest city with 8.6 million inhabitants
  • With 10 locations in Lima, Farmacia Universal S.A.C. is an established magistral formulation laboratory and pharmacy
  • Khiron Perú SA has already obtained certifications as a Pharmaceutical Entity with Good Storage Practices (GSP), a crucial prerequisite for import and commercialization license applications in Peru
  • The Company obtained approval of its security protocols from the Anti-Narcotics Unit of the Ministry of Interior (DIRANDRO) in December 2019, and subsequently submitted its application for import license for medical cannabis
  • Khiron recently announced high-THC cultivation and manufacturing quotas in Colombia and intends to ship high-THC branded medical products to Peru
  • With a population of 32 million, Peru’s medical cannabis market is estimated to be worth $99 million (Prohibition Partners)

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQB:KHRNF, Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced the Company has entered into an exclusive 2-year agreement with Farmacia Universal S.A.C. of Perú, a leading pharmacy chain and manufacturing laboratory based in Lima, to manufacture and distribute Khiron-branded medical cannabis magistral preparations in Perú.


In Peru, only registered pharmaceutical establishments who have fulfilled GSP requirements are authorized to participate in wholesale import and commercialization of cannabis products. Khiron currently holds the necessary license that certifies the Company as a registered pharmaceutical establishment and is one of the first cannabis companies in the country to have received GSP certification from Peru’s Directorate General of Drug Supplies and Drugs (DIGEMID). The Company expects to begin sales in Peru once it obtains its import license from DIGEMID and Farmacia Universal S.A.C. receives authorization for commercialization from DIGEMID.

“Khiron is currently the only Colombian Company with high-THC quotas for export purposes, including into Peru, and considers the country one of the key medical cannabis markets in Latam. Based on our regulatory expertise, Khiron has demonstrated an ability to work with the Peruvian regulatory framework and believes that it will be successful in securing additional permits.” Comments Andres Galofre, Khiron VP, Business Development. “Our clinics, with 120,000 patients, provide a model we can replicate in different jurisdictions, including Peru, subject to their regulatory framework.”

About Farmacia Universal
Founded in 1934, Farmacia Universal S.A.C. (in English: Universal Pharmacy), is a well-known Peruvian pharmacy chain, based in Lima. Farmacia Universal S.A.C. has 10 well distributed point of sales, and is a leader in the pharmaceutical preparations sector in Perú.

Farmacia Universal S.A.C. also sells pharmaceutical, surgical and orthopedics products, among others, differentiating its brand with premium service to customers and patients. CEO, Dolores Guevara, has being recognized as one of the LEC (business leaders of change) in Perú, awarded by EY, El Comercio & ASBANC.

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Visit Khiron online at www.khiron.ca and on Instagram @khironlife

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN, OTC:KHRNF) for an Investor Presentation.

Source

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in the commercialization of natural pozzolans to reduce the carbon footprint of cement production, is pleased to announce that it has expanded the confirmed bedrock source for the nickel in soil anomaly that PLAN reported on August 5 and 17, 2020 on its 100% owned Heffley Creek  Metals and Pozzolan Property in BC.  PLAN also reports multiple samples with anomalous levels of chromium. The latest sampling has identified  a correlation between the elevated nickel and elevated chromium values.

Based on the soil survey results reported on August 5, 2020 and confirmation of a bedrock source reported on August 17, 2020 , PLAN continues its systematic rock sampling program to confirm the soil sample results and to define the limits of the nickel in bedrock anomaly.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its fiscal 2020 financial results for the twelve-month period ended June 30, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

FY2020 Year End Financial Highlights

Keep reading... Show less

America’s #1 Cannabis Oil Brand is Now Available in 15 States

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the United States announced today that it has expanded its award-winning line of Select Oil brand products to its 15 th state, Illinois – the nation’s second-largest adult-use market after California – starting with its Select Elite Live cannabis oil cartridges.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN)(OTCQX: HERTF) (“Heritage” or the “Company”), today announced that it has executed a binding letter of intent (“LOI”) with IntelGenx Corp. (TSXV:IGX)(OTCQB:IGXT) (“IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, for the supply of filmstrip products containing CBD (“CBD Filmstrips”) for the Canadian and Australian markets.

Pursuant to the LOI and subject to entering into a Definitive Supply Agreement and the satisfaction of customary closing conditions, IntelGenx will manufacture filmstrips containing 10 mg of CBD using its VersaFilm® technology, for distribution and sale in Canada and Australia. In addition to receiving a manufacturing margin, IntelGenx will also receive a double-digit royalty on the gross margin based on product sales. Heritage will supply CBD material for IntelGenx’s filmstrip manufacture and supply in Canada and Australia on a non- and semi-exclusive basis, respectively. The LOI contemplates an option on future co-development of CBD and THC filmstrips using proprietary technology from both companies, under certain conditions.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) announces that it has received a Natural Health Product (“NHP”) number (#80105697) from Health Canada for its plant-based, antimicrobial, antiseptic skin ointment. This product was developed after promising results from the Company’s research of certain plant-based compounds for antimicrobial activity against pathogens for potential antiviral treatments. This will be Better Plants fourth Health Canada approval in 2020.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/67076_3977df9e1467bacd_001.jpg

Keep reading... Show less